Humacyte, Inc.

NASDAQ: HUMA · Healthcare · Biotechnology

PublicHQ Durham, NC · DurhamCIK 0001818382Reports USD

#792 of 1,418 Healthcare companies by revenue

EA Score

27D

FH 23DQ 26GM —SS 54

v0.1 · 55/100 weight · provisional

↑ workforce scale, market scale · ↓ disclosure history, return on equity

Methodology →

Revenue TTM

$2.1M

Rev growth YoY (TTM)

-73.6%

Net income (FY)

-$40.8M

Employees

184

as of 2026-08-14

Market cap

$92.4M

as of 2026-08-14

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$2.0M$2.0M2025

Net income-$40.8M-$40.8M2025

Operating income-$108.1M-$108.1M2025

Total assets$116.4M$116.4M2025

Liabilities$113.3M$113.3M2025

Equity$3.1M$3.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Humacyte, Inc.’s revenue?

Humacyte, Inc. booked $2.0M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -2003.6% net margin.

Peers · Healthcare

Cyclerion Therapeutics, Inc.40D HealthLynked Corp.34D 20/20 Biolabs Inc.29D Nutriband Inc.52D Dianthus Therapeutics, Inc.49D Cocrystal Pharma, Inc.31D

Neighbors

Durham →

IQVIA Holdings Inc.$16.3B79B+BioCryst Pharmaceuticals, Inc.$874.8M76B+Fortrea Holdings Inc.$2.7B50D Wolfspeed Inc.$757.6M44D Bioventus Inc.$568.1M66B NET Power Inc.$029D

Key facts

CEOLaura E. Niklason

SectorHealthcare

IndustryBiotechnology

HeadquartersDurham, NC

ExchangeNASDAQ: HUMA

Employees184

IPO date2020-12-01

Latest filings

10-Q2026-08-12 8-K2026-08-12 8-K2026-07-31 8-K2026-06-11 8-K2026-06-10 8-K2026-06-09 8-K2026-06-05 10-Q2026-05-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.